The role of coronary microvascular dysfunction in the pathogenesis of heart failure with preserved ejection fraction

Heart failure with preserved ejection fraction (HFpEF) is a common condition with few effective therapies and hence represents a major healthcare burden. The clinical syndrome of HFpEF can be caused by varying pathophysiological processes, with coronary microvascular dysfunction (CMD) proposed as on...

Full description

Bibliographic Details
Published in:	American Heart Journal Plus
Main Authors:	Becker Al-Khayatt, Divaka Perera, Haseeb Rahman
Format:	Article
Language:	English
Published:	Elsevier 2024-05-01
Subjects:	HFpEF CMD ANOCA
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666602224000302

Similar Items

Bibliometric and visual analysis of coronary microvascular dysfunction
by: Xiaoxiao Lin, et al.
Published: (2022-11-01)

Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta‐analysis
by: Domenico D'Amario, et al.
Published: (2024-08-01)

Regional differences and coronary microvascular dysfunction in heart failure with preserved ejection fraction
by: Mikael Erhardsson, et al.
Published: (2023-12-01)

Impact of severe obesity on exercise performance in heart failure with preserved ejection fraction
by: Satyam Sarma, et al.
Published: (2020-11-01)

The role of cardiac magnetic resonance imaging in the assessment of heart failure with preserved ejection fraction
by: Clement Lau, et al.
Published: (2022-07-01)

Distinct implications of body mass index in different subgroups of nonobese patients with heart failure with preserved ejection fraction: a latent class analysis of data from the TOPCAT trial
by: Bin Dong, et al.
Published: (2022-11-01)

Prognostic significance of the HFA‐PEFF score in patients with heart failure with preserved ejection fraction
by: Yohei Sotomi, et al.
Published: (2021-06-01)

Non-coding RNAs in the pathophysiology of heart failure with preserved ejection fraction
by: Elisabeth A. Jalink, et al.
Published: (2024-01-01)

Multimodality assessment of heart failure with preserved ejection fraction skeletal muscle reveals differences in the machinery of energy fuel metabolism
by: Payman Zamani, et al.
Published: (2021-08-01)

Cardiometabolic heart failure with preserved ejection fraction: from molecular signatures to personalized treatment
by: Era Gorica, et al.
Published: (2025-07-01)

Cardiopulmonary exercise testing as a prognosis‐assessing tool in heart failure with preserved ejection fraction
by: C. Rozados daConceicao, et al.
Published: (2025-06-01)

Proteomics and Precise Exercise Phenotypes in Heart Failure With Preserved Ejection Fraction: A Pilot Study
by: Ravi V. Shah, et al.
Published: (2023-11-01)

Myocardial RNA Sequencing Reveals New Potential Therapeutic Targets in Heart Failure with Preserved Ejection Fraction
by: José M. Inácio, et al.
Published: (2023-07-01)

Effects of Continuous Accelerated Pacing on Cardiac Structure and Function in Patients With Heart Failure With Preserved Ejection Fraction: Insights From the myPACE Randomized Clinical Trial
by: Kramer J. Wahlberg, et al.
Published: (2024-01-01)

Effects of different exercise modalities on cardiac dysfunction in heart failure with preserved ejection fraction
by: David Bode, et al.
Published: (2021-06-01)

Laboratory and Metabolomic Fingerprint in Heart Failure with Preserved Ejection Fraction: From Clinical Classification to Biomarker Signature
by: Alberto Palazzuoli, et al.
Published: (2023-01-01)

Sodium‐glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta‐analysis
by: Arjun K. Pandey, et al.
Published: (2022-04-01)

Impact of Voluntary Exercise on Systemic Inflammation in a 2‐Hit Model of Heart Failure With Preserved Ejection Fraction
by: Heather Quiriarte, et al.
Published: (2025-02-01)

Right Ventricular‐Vascular Uncoupling Predicts Pulmonary Hypertension in Clinically Diagnosed Heart Failure With Preserved Ejection Fraction
by: Zheng‐Wei Chen, et al.
Published: (2024-01-01)

Leucocyte count predicts cardiovascular risk in heart failure with preserved ejection fraction: insights from TOPCAT Americas
by: Navkaranbir S. Bajaj, et al.
Published: (2020-08-01)

Inflammation as a therapeutic target in heart failure with preserved ejection fraction
by: Zhen Hui Peh, et al.
Published: (2023-06-01)

Carbohydrate antigen-125 (CA125): a marker of right ventricular dysfunction and poor prognosis in heart failure with preserved ejection fraction
by: Sher May Ng, et al.
Published: (2025-10-01)

Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
by: Mark Sweeney, et al.
Published: (2020-09-01)

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction
by: Shuo Xu, et al.
Published: (2025-04-01)

The clinical relevance of quality of life in heart failure patients with preserved ejection fraction
by: Masahiro Seo, et al.
Published: (2023-04-01)

Hospitalized patients and stimulant use-associated heart failure: importance of ejection fraction and related risk factors
by: Akshat Agrawal, et al.
Published: (2025-07-01)

The Prognostic Value of Anemia in Patients with Preserved, Mildly Reduced and Recovered Ejection Fraction
by: Anita Pintér, et al.
Published: (2022-02-01)

Large Animal Models of Heart Failure: Reduced vs. Preserved Ejection Fraction
by: Christopher J. Charles, et al.
Published: (2020-10-01)

Astragaloside IV alleviates inflammation and improves myocardial metabolism in heart failure mice with preserved ejection fraction
by: Xiao Wang, et al.
Published: (2024-11-01)

Prognostic value of Growth differentiation factors 15 in Acute heart failure patients with preserved ejection fraction
by: Dan Yin, et al.
Published: (2023-04-01)

Validation of heart failure algorithm for diagnosing heart failure with preserved ejection fraction: a meta‐analysis
by: Shu Li, et al.
Published: (2023-08-01)

Current Understanding of Molecular Pathophysiology of Heart Failure With Preserved Ejection Fraction
by: Heidi Budde, et al.
Published: (2022-07-01)

Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction
by: Bence Hegyi, et al.
Published: (2022-12-01)

Heart Failure With Preserved Ejection Fraction and Obesity
by: Arjun Sinha, MD, et al.
Published: (2020-01-01)

Real‐world clinical diagnostics of heart failure patients with reduced or preserved ejection fraction
by: Jenni Huusko, et al.
Published: (2020-06-01)

Small Heart Size and Premature Death in 366,484 Individuals With Normal Ejection Fraction
by: Stephanie J. Rowe, BBiomed, MD, et al.
Published: (2025-01-01)

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction
by: L. Healy, et al.
Published: (2025-04-01)

Age‐stratified profiles and outcomes of patients with heart failure with preserved ejection fraction
by: Shinsuke Yamanaka, et al.
Published: (2024-08-01)

p53‐Dependent Mitochondrial Compensation in Heart Failure With Preserved Ejection Fraction
by: Xiaonan Chen, et al.
Published: (2022-06-01)

Mice with endothelial cell‐selective adhesion molecule deficiency develop coronary microvascular rarefaction and left ventricle diastolic dysfunction
by: Vadym Buncha, et al.
Published: (2023-03-01)